Abstract
Astemizole, a non-sedating histamine H1 receptor blocker, is widely known to cause cardiac arrhythmia, which prolongs the QT interval. However, the precise molecular mechanism involved in antihistamine-induced cardiovascular adverse effects other than hERG channel inhibition is still unclear. In this study, we used DNA microarray analysis to detect the mechanisms involved in life-threatening adverse effects caused by astemizole. Rat primary cardiomyocytes were treated with various concentrations of astemizole for 24 h and the corresponding cell lysates were analyzed using a DNA microarray. Astemizole altered the expression profiles of genes involved in calcium transport/signaling. Using qRT-PCR analysis, we demonstrated that, among those genes, p21 (Cdc42/Rac)-activated kinase 1 (pak1) mRNA was downregulated by treatment with terfenadine and astemizole. Astemizole also reduced pak1 protein levels in rat cardiomyocytes. In addition, astemizole decreased pak1 mRNA and protein levels in H9c2 cells and induced an increase in cell surface area (hypertrophy) and cytotoxicity. Fingolimod hydrochloride (FTY720), a pak1 activator, inhibited astemizole-induced hypertrophy and cytotoxicity in H9c2 cells. These results suggest that antihistamine-induced cardiac adverse effects are associated with pak1 expression and function.
Similar content being viewed by others
References
Aplin AE, Juliano RL (1999) Integrin and cytoskeletal regulation of growth factor signaling to the MAP kinase pathway. J Cell Sci 112(5):695–706
Ashoor R, Yafawi R, Jessen B, Lu S (2013) The contribution of lysosomotropism to autophagy perturbation. PloS One 8:e82481
Barbey JT, Anderson M, Ciprandi G, Frew AJ, Morad M, Priori SG, Ongini E, Affrime MB (1999) Cardiovascular safety of second-generation antihistamines. Am J Rhinol 13:235–243
Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT (1995) A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 80:795–803
Davis MJ, Wu X, Nurkiewicz TR, Kawasaki J, Gui P, Hill MA, Wilson E (2002) Regulation of ion channels by integrins. Cell Biochem Biophys 36:41–66
De Ponti F, Poluzzi E, Montanaro N (2000) QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience. Eur J Clin Pharmacol 56:1–18
Delgado LF, Pferferman A, Sole D, Naspitz CK (1998) Evaluation of the potential cardiotoxicity of the antihistamines terfenadine, astemizole, loratadine, and cetirizine in atopic children. Ann Allerg Asthma Immunol 80:333–337
Dubuske LM (1999) Second-generation antihistamines: the risk of ventricular arrhythmias. Clin Ther 21:281–295
Frey N, Katus HA, Olson EN, Hill JA (2004) Hypertrophy of the heart: a new therapeutic target? Circulation 109:1580–1589
Gralinski MR (2000) The assessment of potential for QT interval prolongation with new pharmaceuticals: impact on drug development. J Pharmacol Toxicol Methods 43:91–99
Howarth PH, Emanuel MB, Holgate ST (1984) Astemizole, a potent histamine H1-receptor antagonist: effect in allergic rhinoconjunctivitis, on antigen and histamine induced skin weal responses and relationship to serum levels. Br J Clin Pharmacol 18:1–8
Ikeda S, Oka H, Matunaga K, Kubo S, Asai S, Miyahara Y, Osaka A, Kohno S (1998) Astemizole-induced torsades de pointes in a patient with vasospastic angina. Jpn Circ J 62:225–227
Jeong K, Kwon H, Min C, Pak Y (2009) Modulation of the caveolin-3 localization to caveolae and STAT3 to mitochondria by catecholamine-induced cardiac hypertrophy in H9c2 cardiomyoblasts. Exp Mol Med 41:226–235
Ke Y, Lei M, Solaro RJ (2008) Regulation of cardiac excitation and contraction by p21 activated kinase-1. Prog Biophys Mol Biol 98:238–250
Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH (1991) Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 114:345–352
Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, Murabito JM, Vasan RS (2002) Long-term trends in the incidence of and survival with heart failure. N Engl J Med 347:1397–1402
Liu W, Zi M, Naumann R, Ulm S, Jin J, Taglieri DM, Prehar S, Gui J, Tsui H, Xiao RP, Neyses L, Solaro RJ, Ke Y, Cartwright EJ, Lei M, Wang X (2011) Pak1 as a novel therapeutic target for antihypertrophic treatment in the heart. Circulation 124:2702–2715
Olasinska-Wisniewska A, Olasinski J, Grajek S (2014) Cardiovascular safety of antihistamines. Postepy Dermatol Alergol 31:182–186
Paakkari I (2002) Cardiotoxicity of new antihistamines and cisapride. Toxicol Lett 127:279–284
Park MJ, Lee KR, Shin DS, Chun HS, Kim CH, Ahn SH, Bae MA (2013) Predicted drug-induced bradycardia related cardio toxicity using a zebrafish in vivo model is highly correlated with results from in vitro tests. Toxicol Lett 216:9–15
Pietrzkowicz M, Grzelewska-Rzymowska I (1999) Second generation topical antihistaminics. Pol Merkur Lek 6:277–280
Reagan-Shaw S, Nihal M, Ahmad N (2008) Dose translation from animal to human studies revisited. FASEB J 22:659–661
Sheehan KA, Ke Y, Solaro RJ (2007) p21-Activated kinase-1 and its role in integrated regulation of cardiac contractility. Am J Physiol Regul Integr Comp Physiol 293:R963–R973
Sugiyama A, Aye NN, Katahira S, Saitoh M, Hagihara A, Matsubara Y, Hashimoto K (1997) Effects of nonsedating antihistamine, astemizole, on the in situ canine heart assessed by cardiohemodynamic and monophasic action potential monitoring. Toxicol Appl Pharmacol 143:89–95
Taglialatela M, Pannaccione A, Castaldo P, Giorgio G, Zhou Z, January CT, Genovese A, Marone G, Annunziato L (1998) Molecular basis for the lack of HERG K+ channel block-related cardiotoxicity by the H1 receptor blocker cetirizine compared with other second-generation antihistamines. Mol Pharmacol 54:113–121
Taglialatela M, Castaldo P, Pannaccione A, Giorgio G, Genovese A, Marone G, Annunziato L (1999) Cardiac ion channels and antihistamines: possible mechanisms of cardiotoxicity. Clin Exp Allergy 29(Suppl 3):182–189
Tsui H, Zi M, Wang S, Chowdhury SK, Prehar S, Liang Q, Cartwright EJ, Lei M, Liu W, Wang X (2015) Smad3 couples pak1 with the antihypertrophic pathway through the E3 ubiquitin ligase, Fbxo32. Hypertension 66:1176–1183
Van Der Wees CG, Bax WH, Van Der Valk EJ, Van Der Laarse A (2006) Integrin stimulation induces calcium signaling in rat cardiomyocytes by a NO-dependent mechanism. Pflugers Arch 451:588–595
Welch MJ, Meltzer EO, Simons FE (2002) H1-antihistamines and the central nervous system. Clin Allergy Immunol 17:337–388
Wu X, Sun Z, Foskett A, Trzeciakowski JP, Meininger GA, Muthuchamy M (2010) Cardiomyocyte contractile status is associated with differences in fibronectin and integrin interactions. Am J Physiol Heart Circ Physiol 298:H2071–H2081
Yamamoto K, Tamura T, Imai R, Yamamoto M (2001) Acute canine model for drug-induced Torsades de Pointes in drug safety evaluation-influences of anesthesia and validation with quinidine and astemizole. Toxicol Sci 60:165–176
Yang Y, Wu X, Gui P, Wu J, Sheng JZ, Ling S, Braun AP, Davis GE, Davis MJ (2010) Alpha5beta1 integrin engagement increases large conductance, Ca2+-activated K+ channel current and Ca2+ sensitivity through c-src-mediated channel phosphorylation. J Biol Chem 285:131–141
Acknowledgments
This research was supported by a grant (15181MFDS482, 08171MFDS503, 07151MFDS671) from the Ministry of Food and Drug Safety.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare no conflict of interest.
Additional information
Jaesuk Yun and So Young Kim contributed equally to this work.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Yun, J., Kim, S.Y., Yoon, K.S. et al. P21 (Cdc42/Rac)-activated kinase 1 (pak1) is associated with cardiotoxicity induced by antihistamines. Arch. Pharm. Res. 39, 1644–1652 (2016). https://doi.org/10.1007/s12272-016-0840-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-016-0840-7